Literature DB >> 24337465

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.

Irina Lonskaya1, Michaeline L Hebron, Nicole M Desforges, Joel B Schachter, Charbel E-H Moussa.   

Abstract

UNLABELLED: Alzheimer's disease (AD) is a neurodegenerative disorder associated with amyloid accumulation and autophagic changes. Parkin is an E3 ubiquitin ligase involved in proteasomal and autophagic clearance. We previously demonstrated decreased parkin solubility and interaction with the key autophagy enzyme beclin-1 in AD, but tyrosine kinase inhibition restored parkin-beclin-1 interaction. In the current studies, we determined the mechanisms of nilotinib-induced parkin-beclin-1 interaction, which leads to amyloid clearance. Nilotinib increased endogenous parkin levels and ubiquitination, which may enhance parkin recycling via the proteasome, leading to increased activity and interaction with beclin-1. Parkin solubility was decreased and autophagy was altered in amyloid expressing mice, suggesting that amyloid stress affects parkin stability, leading to failure of protein clearance via the lysosome. Isolation of autophagic vacuoles revealed amyloid and parkin accumulation in autophagic compartments but nilotinib decreased insoluble parkin levels and facilitated amyloid deposition into lysosomes in wild type, but not parkin(-/-) mice, further underscoring an essential role for endogenous parkin in amyloid clearance. These results suggest that nilotinib boosts the autophagic machinery, leading to increased level of endogenous parkin that undergoes ubiquitination and interacts with beclin-1 to facilitate amyloid clearance. These data suggest that nilotinib-mediated autophagic changes may trigger parkin response via increased protein levels, providing a therapeutic strategy to reduce Aβ and Tau in AD. KEY MESSAGE: Parkin solubility (stability) is decreased in AD and APP transgenic mice. Nilotinib-induced autophagic changes increase endogenous parkin level. Increased parkin level leads to ubiquitination and proteasomal recycling. Re-cycling decreases insoluble parkin and increases parkin-beclin-1 interaction. Beclin-1-parkin interaction enhances amyloid clearance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337465      PMCID: PMC3975659          DOI: 10.1007/s00109-013-1112-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  46 in total

1.  Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway.

Authors:  James A Olzmann; Lih-Shen Chin
Journal:  Autophagy       Date:  2007-10-15       Impact factor: 16.016

2.  Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation.

Authors:  H Xu; D Sweeney; R Wang; G Thinakaran; A C Lo; S S Sisodia; P Greengard; S Gandy
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.

Authors:  Pascal Derkinderen; Timothy M E Scales; Diane P Hanger; Kit-Yi Leung; Helen L Byers; Malcolm A Ward; Christof Lenz; Caroline Price; Ian N Bird; Timothy Perera; Stuart Kellie; Ritchie Williamson; Wendy Noble; Richard A Van Etten; Karelle Leroy; Jean-Pierre Brion; C Hugh Reynolds; Brian H Anderton
Journal:  J Neurosci       Date:  2005-07-13       Impact factor: 6.167

4.  Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss.

Authors:  G William Rebeck; Hyang-Sook Hoe; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

5.  The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice.

Authors:  Fiona Pickford; Eliezer Masliah; Markus Britschgi; Kurt Lucin; Ramya Narasimhan; Philipp A Jaeger; Scott Small; Brian Spencer; Edward Rockenstein; Beth Levine; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

6.  The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice.

Authors:  Juan Perucho; Maria J Casarejos; Isabel Rubio; José A Rodriguez-Navarro; Ana Gómez; Israel Ampuero; Izaskun Rodal; Rosa M Solano; Eva Carro; Justo García de Yébenes; Maria A Mena
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

7.  Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.

Authors:  I Lonskaya; M L Hebron; N K Algarzae; N Desforges; C E-H Moussa
Journal:  Neuroscience       Date:  2012-12-20       Impact factor: 3.590

8.  Isolation of autophagic vacuoles from rat liver: morphological and biochemical characterization.

Authors:  L Marzella; J Ahlberg; H Glaumann
Journal:  J Cell Biol       Date:  1982-04       Impact factor: 10.539

9.  A molecular explanation for the recessive nature of parkin-linked Parkinson's disease.

Authors:  Donald E Spratt; R Julio Martinez-Torres; Yeong J Noh; Pascal Mercier; Noah Manczyk; Kathryn R Barber; Jacob D Aguirre; Lynn Burchell; Andrew Purkiss; Helen Walden; Gary S Shaw
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance.

Authors:  Irina Lonskaya; Michaeline L Hebron; Nicole M Desforges; Alexander Franjie; Charbel E-H Moussa
Journal:  EMBO Mol Med       Date:  2013-07-04       Impact factor: 12.137

View more
  54 in total

Review 1.  Development of autophagy inducers in clinical medicine.

Authors:  Beth Levine; Milton Packer; Patrice Codogno
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

Review 2.  The c-Abl inhibitor in Parkinson disease.

Authors:  Zhi-Hua Zhou; Yun-Fan Wu; Xue-Min Wang; Yong-Zhu Han
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 3.  Insulin resistance in Alzheimer's disease.

Authors:  Kelly T Dineley; Jordan B Jahrling; Larry Denner
Journal:  Neurobiol Dis       Date:  2014-09-16       Impact factor: 5.996

Review 4.  Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.

Authors:  Alan J Fowler; Charbel E-H Moussa
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

Review 5.  Autophagy in neurodegenerative diseases: pathogenesis and therapy.

Authors:  Fang Guo; Xinyao Liu; Huaibin Cai; Weidong Le
Journal:  Brain Pathol       Date:  2017-08-06       Impact factor: 6.508

Review 6.  Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism.

Authors:  Darius Ebrahimi-Fakhari; Afshin Saffari; Lara Wahlster; Jenny Lu; Susan Byrne; Georg F Hoffmann; Heinz Jungbluth; Mustafa Sahin
Journal:  Brain       Date:  2015-12-29       Impact factor: 13.501

Review 7.  TDP-43 in the spectrum of MND-FTLD pathologies.

Authors:  Lanier Heyburn; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2017-07-04       Impact factor: 4.314

Review 8.  Autophagy and neurodegeneration.

Authors:  Rebecca A Frake; Thomas Ricketts; Fiona M Menzies; David C Rubinsztein
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

9.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.

Authors:  Alan J Fowler; Michaeline Hebron; Kaluvu Balaraman; Wangke Shi; Alexander A Missner; Jonathan D Greenzaid; Timothy L Chiu; Clementina Ullman; Ethan Weatherdon; Val Duka; Yasar Torres-Yaghi; Fernando L Pagan; Xiaoguang Liu; Habtom Ressom; Jaeil Ahn; Christian Wolf; Charbel Moussa
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.